The French Trade Commission UBIFRANCE in London will showcase five innovative companies from the biotechnology and pharmaceutical sectors at the Genesis Conference, which will be held on 9 December 2010 at the Queen Elizabeth II Conference Centre in central London. These French companies are aiming to establish new professional contacts and explore business opportunities between France and the UK.
The Genesis Conference, which is organised by the ONE NUCLEUS cluster (London and Cambridge), and, this year, celebrates its tenth anniversary, is a key event in the life-sciences sector. For the fifth consecutive year, Genesis will give five innovative French companies the opportunity to showcase their services and expertise, thanks to the support provided by the French Trade Commission UBIFRANCE in London.
The companies taking part in the French Pavilion are as follows.
ALCIMED: Founded in 1993, ALCIMED assists decision-makers in terms of their strategic development and their positioning. ALCIMED acts as the interface between science and business, and helps clients – be they sales and marketing directors, corporate-level directors, or R&D managers – to grasp new opportunities, adapt to potential threats such as changes in regulation, come up with novel solutions, and translate ideas into practice.
ALCIMED employs 180 people across four countries and will open its London office in 2012.
Aureus Pharma: Aureus Pharma provides a range of scientific knowledge solutions enabling biopharmaceutical companies to better understand the chemical and biological space around major therapeutic targets and, therefore, to better identify drug profiles. Aureus Pharma’s information solutions streamline the discovery process for many of the world’s most successful biopharmaceutical companies and leading research institutions.
The new Aureus Sciences Web Portal will be released in 2011, which will allow professionals in the pharmaceutical and biotech sectors to access a collaborative network, as well as editorial content, and specific dashboards.
Bertin Pharma: Bertin Pharma offers a comprehensive and integrated range of products and services throughout the drug-development value chain. The company was created out of a merger between four well-established French companies – Biotec Centre, Ellipse Pharmaceuticals, IDPS and SPI-Bio. Bertin Pharma now employs over 100 pharmacists, scientists and technicians.
Bertin Pharma positions itself as “an ideal partner for preclinical, clinical and pharmaceutical development, as well as bio-safety studies”. The company offers expertise, innovative technologies, dedicated technical platforms, environments with appropriate quality standards (GLP, GMP and GDP) and specific competencies applied to biologics.
HISTALIM: HISTALIM is a technical platform for histology, cytology and molecular biology, offering a large range of services addressing the pharmaceutical and CRO sectors.
HISTALIM is now embarking on its next stage of development, in the hope of becoming the reference platform for histology, cytology and molecular biology for every application type within the next five years. Its goal is also to become a key partner for method-designing and image-analysis applications in histotechnology.
Keyrus Biopharma: Keyrus Biopharma is a European CRO offering a complete range of services from preclinical to post-marketing studies. Keyrus Biopharma divides its expertise into five main areas: clinical operations, biometry, medical writing, pharmacovigilance and quality assurance. With over 12 years’ experience in clinical trials, Keyrus Biopharma has worked with a number of major clients in the fields of medicine, nutrition, vaccines, biotechnology, medical devices and cosmetics.
A rapidly expanding company, Keyrus Biopharma plans to invest in the British market in the next two years in order to meet the demand of its clients.
UBIFRANCE
